SEC For	m 4																				
FORM 4 UNITED				D STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549													OMB APPROVAL				
Section 16. Form 4 or Form 5 obligations may continue. See							AT OF CHANGES IN BENEFICIAL OWNERSHIP d pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940											OMB Number: 3235-0287 Estimated average burden hours per response: 0.5			
1. Name and Address of Reporting Person [*] <u>SCHWARTZ BRIAN</u> (Last) (First) (Middle) C/O CYCLACEL PHARMACEUTICALS, INC., 200 CONNELL DRIVE SUITE 1500					<u>C</u>	2. Issuer Name and Ticker or Trading Symbol Cyclacel Pharmaceuticals, Inc. [CYCC] 3. Date of Earliest Transaction (Month/Day/Year) 06/14/2022									Relationship of Reporting Person(s) to Issuer leck all applicable) X Director 10% Owner Officer (give title Other (specify below) below)				ner		
200 CONNELL DRIVE, SUITE 1500 (Street) BERKELEY HEIGHTS NJ 07922 (City) (State) (Zip)					4.1	Line) X Form file										bint/Group Filing (Check Applicable ed by One Reporting Person ed by More than One Reporting					
(City)	(3	,	,	Daris	<u>etiv</u>				auirod	Dia			onofi		. Ournad						
Table I - Non-Deriva 1. Title of Security (Instr. 3) 2. Transa Date (Month/D)					action	ction 2A. Deemed Execution I			, 3. Transa Code (3. 4. S Transaction Dis Code (Instr. 5)		Securities Acquired (A) posed Of (D) (Instr. 3,) or	5. Amou Securitie Beneficia Owned F	nt of 6. es Fo ally (D) Following (I)		orm: Direct)) or Indirect) (Instr. 4)	7. Nature of Indirect Beneficial Ownership		
									Code	v	Amount	(A (D) or F	Price		nsaction(s) htr. 3 and 4)			(Instr. 4)		
Common Stock 06/14					4/202	/2022			Α		15,822 ⁽¹⁾ A		A	\$ <mark>0</mark>	19,	,383		D			
		-	Fable II -								osed of, onvertil				Owned						
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution I if any (Month/Day	Date,	I. Fransaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Ex Expiration (Month/D	n Date	of Securitie		rities ving ive Sec	urity	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)		
					Code	v	(A)	(D)	Date Exercisat		Expiration Date	Title	or Nui of	ount mber ares							
Stock Option (right to buy)	\$1.11	06/14/2022			A		31,645		06/14/202	23 0	06/14/2032	Commo Stock	^{on} 31	,645	\$0 ⁽²⁾	31,64	5	D			

Explanation of Responses:

1. The reporting person received an award of 15,822 restricted stock units on June 14, 2022, which shall vest in full on June 14, 2023.

2. These options were granted to Dr. Schwartz for his services as a member of the board of directors of Cyclacel Pharmaceuticals, Inc.

/s/ Brian Schwartz

** Signature of Reporting Person

<u>06/16/2022</u> Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

 * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.